Fresh from ASCO 2025: What recent oncology advancements mean for your commercial strategy

Join Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, and Kevin Entwistle, VP of Precision Medicine Strategy, as they unpack the key takeaways from ASCO 2025 and explore how the latest oncology data can shape your commercial strategy.

In this expert-led discussion, you'll hear about:

• How to translate scientific insights into actionable strategies for pharma and biotech teams
• Commercial implications of novel ADCs, gene & cell therapies, and multi-cancer detection
• The growing impact of AI and computational pathology in clinical decision-making
• Breakthrough clinical data from trials like SERENA-6, MATTERHORN, ATOMIC, and AMPLITUDE
• Advances in ctDNA and MRD detection, including MONSTAR-SCREEN-3 and DYNAMIC-III
• The evolving role of biomarkers and diagnostic testing in precision medicine

Connect with the Speakers

• Susanne Munksted: https://www.linkedin.com/in/susanne-munksted-9169031/
• Kevin Entwistle: https://www.linkedin.com/in/kevin-entwistle-73335520/

 

🌐 Learn more about Diaceutics: https://www.diaceutics.com/contact-us